← All reports
GXI.DE12/09/2025

Morpheus Research Short Report on GXI.DE

By Morpheus ResearchView original source ↗
$24.7
Open on report
$26.28
Close on report
6.4%
% since report
Full history, earnings & live data

GERRESHEIMER AG $GXI

Morpheus Research • Published December 9, 2025 • XETRA: GXI.DE

"A Conflicted Acquisition, Flailing Divestiture & Accounting Games Coming To Roost As Key Weight-Loss Driver At Risk"

🔻 SHORT POSITION

CORE INVESTMENT THESIS

Gerresheimer AG is a dangerously overleveraged packaging company with a key growth driver (CagriSema dual-chamber syringes) facing quality issues, delays, and cannibalization risks from single-chamber alternatives and oral pills.

The ~€800 million Bormioli acquisition was negotiated by a CEO with conflicts of interest with the seller, paid a 10x EBITDA multiple for a loss-making, zero-growth business, and aggressive accounting practices are masking an already deteriorating financial picture. Morpheus Research sees no easy way out.

COMPANY OVERVIEW

Company Name
Gerresheimer AG
Founded 1864 • 161 Years Old
Headquarters
🇩🇪 Germany
XETRA Exchange • Frankfurt
Current Business
Pharma Packaging
40+ Facilities in 16 Countries
Leadership
Uwe Röhrhoff
Interim CEO (Since Oct 2025)
Market Cap
€857 Million
Down ~80% Since Sept 2023
Key Risk
Overleveraged
4.15x Net Debt/EBITDA

KEY FINANCIAL RED FLAGS

Stock Decline
-80%

Since September 2023 peak after profit warnings, CEO departure, and BaFin investigation

Leverage Ratio
4.15x

Net Debt/EBITDA near previous 4.25x covenant threshold; new terms undisclosed

Bormioli Acquisition
€800M

10x EBITDA multiple—"highest in pharma packaging" for a loss-making business

Bormioli Net Loss
-€51.4M

2024 loss accelerating from €8M in 2023; revenue flat to declining

FINANCIAL DETERIORATION

Bormioli Pharma Net Income (€ Millions)

-€7.6M
2023
-€51.4M
2024
Net Loss (576% YoY Increase)

Capitalized Expenditure vs Sales (%)

5.5%
Peers Avg
17%
Gerresheimer
Peer Average
Gerresheimer (3x Higher)

AGGRESSIVE ACCOUNTING PRACTICES

🔴 Development Cost Capitalization

Claims 3-10 year amortization but actual charges imply up to 34 years. Boosted 2024 operating income by ~7%.

🔴 Extended Asset Useful Life

In 2020, extended Sensile Medical technology life from 15 to 25 years (+66%), boosting near-term earnings.

🔴 Borrowing Cost Capitalization

After 15 years of not capitalizing, suddenly started in 2023. €9M capitalized in 2024 (~8% of net income).

🔴 Bad Debt Provisions

Despite record overdue receivables, provisions at 15-year low, boosting operating income ~2.5%.

🔴 One-Off Expense Removal

Adjustments more than doubled from 6.6% to 12.8% of EBITDA in 9M 2025.

🔴 BaFin Investigation

German regulator investigating "bill-and-hold" practices. Employees say it was "common practice all across the business."

CAGRISEMA GROWTH DRIVER AT RISK

⚠️ Quality Issues: Novo Nordisk employees report packaging problems with dual-chamber syringe causing complaints and potential "late stage design change" delays.
⚠️ Single-Chamber Competition: Novo launched trial for single-chamber CagriSema in Dec 2024. "No reason to stay with dual chamber" if it works.
⚠️ No IP Protection: Novo can manufacture dual-chamber syringe in-house or source elsewhere. "Gerresheimer does not have IP on the syringe."
⚠️ Oral Pills Threat: Eli Lilly manufacturing "billions" of pills; Novo going "all in" on pills. Experts expect 40-60% market share for orals.
⚠️ Next-Gen Competition: Amycretin shows excellent results with single-chamber syringe and no "weight loss plateau"—potential CagriSema killer.
⚠️ Revenue at Risk: CagriSema expected to drive €250M by 2027. Delays and competition threaten this key growth driver.

KEY PLAYERS

Dietmar Siemssen
Former CEO (Departed Oct 2025)
Presided over Bormioli acquisition while simultaneously moonlighting as CEO at Triton Partners portfolio company BFC Fahrzeugteile. Former employee: "For me, this is kind of a compliance question."
Bernd Metzner
Former CFO (Departed Aug 2025)
Per former employee: "He was only trying to find topics to do financial engineering on... one of the things he identified was to lower interest cost by capitalizing them."
Triton Partners
Private Equity (Bormioli Seller)
Sold Bormioli for ~€800M at 10x EBITDA—"highest multiple in pharma packaging." Industry expert: "They indeed paid a rich price... Triton was very happy."
BaFin
German Financial Regulator
Launched formal investigation into Gerresheimer's "bill-and-hold" accounting practices in September 2025. Former employees describe it as "common practice all across the business."
Uwe Röhrhoff
Interim CEO (Since Oct 2025)
Tasked with executing molded glass divestiture and turnaround. Former executives say buyers "not exactly lining up" for the distressed assets.
Karin Dorrepaal
Former Director
Served on Gerresheimer board when Bormioli deal was signed. Was member of Triton's Industry Board for 16+ years until March 2024—just 2 months before deal announcement.

ADDITIONAL RED FLAGS

🏭 Chicago Heights Plant: Competitor calls it "complete f*cking dog." Not profitable since 2015. OSHA fined $145K for safety violations. Employees report "many OSHA violations."
📉 Molded Glass Divestiture: Former exec: "The molded business is declining... it's not like people are lining up." High energy costs in Germany make assets unattractive.
💸 Advanced Tech Division: €105M cumulative EBITDA losses, €87.5M CapEx, 25% headcount cuts, €116.7M impairment taken. €196M book value at risk.
🚨 Customer Loss: Lost biggest volume syringe customer at North Macedonia plant—after €100M investment announced in 2024.
📋 Channel Stuffing: Former Bormioli employees describe year-end stuffing via distributor Punto Pack. Estimated €10-15M in inflated revenue.
🔧 Deferred CapEx: Former employees estimate "double digit millions" in deferred maintenance. Bormioli assets described as "old machines" and "aging furnaces."

Morpheus Research's Verdict

According to Morpheus Research, Gerresheimer AG ($GXI) has spent years trying to convince investors it can move upmarket with its "formula G" strategy, but its key growth driver CagriSema faces a litany of risks. The supposedly synergistic Bormioli acquisition appears to be flailing, the debt situation remains unaddressed, and buyers for molded glass are not "lining up." While management downplays the BaFin investigation, interviews indicate the issue could be more prevalent, while years of aggressive accounting practices seem to be propping up an already bleak financial picture.

🔻 MORPHEUS RESEARCH SHORT POSITION

Position: Short ~0.5% of issued share capital

"We see no easy way out."

Disclaimer: This dashboard summarizes Morpheus Research's report. It represents their opinion based on their research. Readers should conduct their own due diligence. This is not financial advice.